



# Insufficient Iterations and Uncertainty Probability Thresholds of Probabilistic Sensitivity Analysis in Economic Evaluation

Yu Xin<sup>1</sup>, Yilin Deng<sup>2</sup>, Jun Hao<sup>3</sup>, Changjin Wu<sup>4</sup>, Yuanyi Cai<sup>5</sup>, Ling Zuo<sup>1</sup>, Wen Hui<sup>1</sup>

<sup>1</sup>West China Hospital of Sichuan University, Chengdu, China, <sup>2</sup> West China School of Public Health and Fourth Hospital, Sichuan University, Chengdu, China, <sup>3</sup> The First Affiliated Hospital of Nanchang University, Nanchang, China, <sup>4</sup> College of Public Health, Chongqing Medical University, Chongqing, China, <sup>5</sup> School of Health Management, China Medical University, Shenyang, China.

Contact: Yu Xin (xinyu1006@scu.edu.cn)  
Wen Hui (huiwen@scu.edu.cn)

## BACKGROUND

- **The Problem:** Probabilistic sensitivity analysis (PSA) often relies on arbitrary iteration counts rather than formal convergence assessment in economic evaluation (EE), risking unstable and unreliable cost-effectiveness probabilities.
- **The Gap:** Even with adequate convergence, PSA results depend on a predefined probability threshold for decision-making, yet formal guidance from health technology assessment agencies remains scarce.

## RESEARCH OBJECTIVE

- **Objective 1:** Verify whether PSA iterations are sufficient to yield stable uncertainty estimates.
- **Objective 2:** Assess how probability thresholds influence cost-effectiveness conclusions when using health-adjusted life years (HALYs) as the primary outcome.


## METHODS

- **Search Strategy:** Full EE published between Jan 1, 2023, and Mar 18, 2025.
- **Quality Filter:** Strictly limited to journals ranked in the top 5% by Journal Impact Factor across 51 Clinical Medicine subcategories.
- **Data Extraction:** Conducted by three trained groups of independent reviewers, capturing:
  - Study Characteristics:* Designs, analytical perspectives, research domains, and outcome types.
  - Analytical Details:* Specific PSA methods, iteration counts, and cost-effectiveness conclusions.


## RESULTS

### 1. Search and Screening Results

An initial literature search identified 591 relevant articles from PubMed database, and after abstract and full-text screening according to inclusion and exclusion criteria, 363 articles were included. Of these, 302 performed PSA.




### 2. The Insufficient Iterations



- Across all studies (n=302), most adopted only 1,000 iterations (35.1%), followed by 10,000 iterations (33.8%).
- Individual-level data studies were most likely to use just 1,000 iterations (40.9%), while modelling studies had the highest proportion of 10,000 iterations (38.6%).
- 3.0% with fewer than 1,000 iterations exhibited risks of underestimated uncertainty analysis, particularly in EE based on individual-level data.

- **Model Convergence Validation Result:** Based on Monte Carlo Error (MCE) calculation for studies with  $\leq 1,000$  iterations, formal validation confirmed notable non-convergence problems in these studies.

### 3. HALYs with a Pre-defined Probability Thresholds



- **Overconfidence:** 37.4% of studies concluding cost-effective failed to meet the 75% probability threshold; 5.0% did not reach even the 50% threshold.
- **Paradoxical Rejection:** 11.1% of studies concluding not cost-effective exceeded the 50% probability threshold.

## CONCLUSIONS

### • Iteration Arbitrariness & Rigor Risk

Empirical, arbitrary selection of 1,000 or 10,000 PSA iterations compromises methodological rigor and overall reliability of economic evaluation.

### • Threshold Consensus Gap

This study demonstrated that identical cost-effectiveness probabilities may yield divergent economic conclusions, driven by a lack of consensus on standardized PSA probability cutoffs.